RADIOPHARMACEUTICALS BASED ON FIBROBLAST ACTIVATION PROTEIN INHIBITORS IN ONCOLOGICAL PRACTICE.

The review is devoted to the application of the new perspective class of radionuclide tracers, based on inhibitors of the fibroblast activation protein (FAP), which is a marker of cancer-associated fibroblasts of microenvironment of most malignant tumors. FAP inhibitors (FAPI) can be labeled by a wide spectrum of radionuclides, which can provide both radionuclide diagnostics and radionuclide therapy. It was showed, that the diagnostic efficacy of FAPI positron emission tomography/computed tomography (PET/CT) in various cancers is similar to 18F-fluorodesoxyglu-cose-PET/CT or superior.